ArticleBritish journal of cancer1994
Serum metalloproteinases and their inhibitors: markers for malignant potential.
Article in British journal of cancer, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00001683 (A Phase I Study of Oral COL-3), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.
- The Role of the Metzincin Superfamily in Prostate Cancer Progression: A Systematic-Like Review.International journal of molecular sciences · 2021Pooled it
- Serum TIMP-1 concentrations are associated with cancer incidence and cancer-related mortality in a population-based cohort.Scientific reports · 2026Article
- The pre-metastatic niche: mechanisms, heterogeneity, and therapeutic opportunities.Molecular cancer · 2026Review
- miR-618: possible control over TIMP-1 and its expression in localized prostate cancer.BMC cancer · 2018Article
- 14-3-3 proteins modulate the ETS transcription factor ETV1 in prostate cancer.Cancer research · 2013Article
- Levels of matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 in gastric cancer.World journal of gastroenterology · 2011Article
- Association of TIMP-4 gene polymorphism with the risk of osteoarthritis in the Korean population.Rheumatology international · 2008Article
- Beyond prostate-specific antigen: alternate serum markers.Prostate cancer and prostatic diseases · 2008Review
- Serum levels of tissue inhibitors of metalloproteinase 2 in patients with systemic sclerosis with duration more than 2 years: correlation with cardiac and pulmonary abnormalities.Mediators of inflammation · 2006Article
- Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer.Urological research · 2005Article
- GnT-V, macrophage and cancer metastasis: a common link.Clinical & experimental metastasis · 2003Review
- Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines.Prostate cancer and prostatic diseases · 2003Article
- A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma.The American journal of pathology · 2001Review
- Adjuvant chemo-/hormonal therapy trials for locally advanced prostate cancer.Current oncology reports · 2000Review
- Immunolocalization of matrix metalloproteinases and their inhibitors in clinical specimens of bone metastasis from breast carcinoma.Clinical & experimental metastasis · 2000Article
- Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer.British journal of cancer · 1999Article
- The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application.International journal of pancreatology : official journal of the International Association of Pancreatology · 1997Review
- Hyaluronidase activity in gynaecological cancer tissues with different metastatic forms.British journal of cancer · 1997Article
- Matrix metalloproteinase inhibitors.Investigational new drugs · 1997Review
- Secretion of matrix metalloproteinase-2 (72 kD gelatinase/type IV collagenase = gelatinase A) by malignant human glioma cell lines: implications for the growth and cellular invasion of the extracellular matrix.Journal of neuro-oncology · 1996Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Death from cancer results from the development of metastases or local progression of tumour. Metastasis and local progression may result from the inappropriate activity of metalloproteinases released by tumour cells or of their regulatory peptides. We have developed quantitative assays for interstitial collagenase, stromelysin 1 and tissue inhibitors of metalloproteinase (TIMP) 1 and 2, which have allowed the study of serum levels of these proteins. Sera from 40 patients with prostatic cancer, stored prior to and after 6 and 12 months' treatment with a gonadotrophin-releasing hormone agonist and an anti-androgen were analysed. Levels were compared with two control groups, comprising 21 patients with active rheumatoid arthritis and 56 age-matched hospital attenders without arthritis or cancer. Contrasting levels have been found in patients with prostatic cancer as compared with hospital controls without cancer and patients with rheumatoid arthritis. Patients with prostatic cancer had higher levels of TIMP-1 and collagenase (P = 0.0001) and lower levels of TIMP-2 (P = 0.003) than controls. Patients with metastatic cancer had significantly higher levels of collagenase than those without metastases (P = 0.02). Patients with rheumatoid arthritis had significantly higher levels of stromelysin than either controls (P = 0.002) or patients with cancer (P = 0.008). Serum tissue inhibitor of metalloproteinase 1 in combination with collagenase levels was as sensitive as prostate-specific antigen as a marker of metastatic disease. These findings provide a basis for the investigation of the role of metalloproteinases and their inhibitors in other malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.